A clinical case of metastatic retroperitoneal paraganglioma

Pheochromocytoma (PCС) and paraganglioma (PG) are malignant neuroendocrine tumors (NEO) of paraganglionic origin, producing biologically active substances and characterized by a variable clinical course. Currently, the main method of treatment of PCС and PG is radical surgical treatment; nevertheless, there is a life-long risk of tumor recurrence as well as distant metastases. Here we present a clinical case of recurrent retroperitoneal PG incidentally detected during hospitalization for decompensated diabetes mellitus (DM). In the case PG caused acute cerebral circulatory failure, arterial hypertension, DM, heart rhythm disorders, potentially preventable with timely diagnosis of the disease. The peculiarity of the detected PG was its recurrent course despite repeated surgical interventions.

1. Mel’nichenko GA, Troshina EA, Bel’tsevich DG., et al. Russian Association of Endocrinologists clinical practice guidelines for diagnosis and treatment of pheochromocytoma and paraganglioma. Endocrine Surgery. 2015;9(3):15-33. (In Russ.) doi: https://doi.org/10.14341/serg2015315-33

2. Aygun N. Pheochromocytoma and paraganglioma: from epidemiology to clinical findings. SiSli Etfal Hastan Tip Bul / Med Bull Sisli Hosp. 2020. doi: https://doi.org/10.14744/semb.2020.18794

3. Ayala-Ramirez M, Feng L, Johnson MM, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011; 96:717-25. doi: https://doi.org/10.1210/jc.2010-1946

4. Ebbehoj A, Stochholm K, Jacobsen SF, Trolle C, Jepsen P, et al. Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study. J Clin Endocrinol Metab. 2021;106:e2251–e2261. doi: https://doi.org/10.1210/clinem/dgaa965

5. Berends AMA, Buitenwerf E, de Krijger RR, Veeger N, van der Horst-Schrivers ANA, et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. Eur J Intern Med. 2018;51:68–73. doi: https://doi.org/10.1016/j.ejim.2018.01.015

6. Kopetschke R, Slisko M, Kilisli A, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009;161(2):355-361. doi: https://doi.org/10.1530/EJE-09-0384

7. McNeil AR, Blok BH, Koelmeyer TD, Burke MP, Hilton JM. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Australian and New Zealand journal of medicine. 2000;30:648–652. doi: https://doi.org/10.1111/j.1445-5994.2000.tb04358.x

8. Lo CY, Lam KY, Wat MS, Lam KS. Adrenal pheochromocytoma remains a frequently overlooked diagnosis. American journal of surgery. 2000;179:212–215. doi: https://doi.org/10.1016/S0002-9610(00)00296-8

9. Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. The Journal of clinical endocrinology and metabolism. 2005;90:2110–6

10. Young WF. Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol Metab Clin North Am. 2000;29(1):159-185. doi: https://doi.org/10.1016/S0889-8529(05)70122-5

11. Leung AA, Pasieka JL, Hyrcza MD, Pacaud D, Dong Y, et al. Epidemiology of pheochromocytoma and paraganglioma: Population-based cohort study. Eur. J. Endocrinol. 2021;184:19–28. doi: https://doi.org/10.1530/EJE-20-0628

12. Gimenez-Roqueplo AP, DahiaPL, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res. 2012;44(5):328–33. doi: https://doi.org/10.1055/s-0031–1301302

13. Beltsevich DG, Melnichenko GA, Kuznetsov NS, et al. Russian Association of Endocrinologists clinical practice guideline for adrenal incidentalomas differential diagnosis. Endocrine Surgery. 2016;10(4):31-42. (In Russ.) doi: https://doi.org/10.14341/serg2016431-42

14. Kyriakopoulos G, Mavroeidi V, Chatzellis E, et al. Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms. Ann Transl Med. 2018;6(12):252. doi: https://doi.org/10.21037/atm.2018.06.27

15. Zuber S, Wesley R, Prodanov T, et al. Clinical utility of chromogranin A in SDHx-related paragangliomas. Eur J Clin Invest. 2014;44(4):365-71. doi: https://doi.org/10.1111/eci.12245

16. Kwon SE, Chapman ER. Synaptophysin regulates the kinetics of synaptic vesicle endocytosis in central neurons. Neuron. 2011; 70(5):847–854

17. Pheochromocytoma / I.I. Dedov, D.G. Beltsevich, N.S. Kuznetsov, G.A. Melnichenko. — M.: Practical medicine, 2005. — 216 p. (In Russ.)

18. Surgical Endocrinology: a guide / Edited by A.P. Kalinin, N.A. Maistrenko, P. S. Vetshev. — St. Petersburg: Peter, 2004. — 900 pages (in Rus.)

19. Local-Regional Recur-rence of Pheochromocytoma/Paraganglioma: Characteristics, Risk Factors and Outcomes. Front Endocrinol (Lausanne). 2021;12:762548. doi: https://doi.org/10.3389/fendo.2021.762548

20. Johnston PC, Mullan KR, Atkinson AB, Eatock FC, Wallace H, Gray M, et al. Recurrence of Phaeochromocytoma and Abdominal Paraganglioma After Initial Surgical Intervention. Ulster Med J. 2015;84(2):102–6

21. Slycke SV, Caiazzo R, Pigny P, Cardot-Bauters C, Arnalsteen L, D’Herbomez M, et al. Local-Regional Recurrence of Sporadic or Syndromic Abdominal Extra-Adrenal Paraganglioma: Incidence, Characteristics, and Outcome. Surgery. 2009;146(6):986–92. doi: https://doi.org/10.1016/j.surg.2009.10.055

22. Shen WT, Grogan R, Vriens M, Clark OH, Duh Q. One Hundred Two Patients With Pheochromocytoma Treated at a Single Institution Since the Introduction of Laparoscopic Adrenalectomy. Arch Surg (Chicago 1960). 2010;145(9):893. doi: https://doi.org/10.1001/archsurg.2010.159

23. Amar L, Fassnacht M, Gimenez-Roqueplo A, Januszewicz A, Prejbisz A, Timmers H, et al. Long-Term Postoperative Follow-Up in Patients With Apparently Benign Pheochromocytoma and Paraganglioma. Horm Metab Res 2012;44(5):385. doi: https://doi.org/10.1055/s-0031-1301339

24. Amar L, Lussy-Lepoutre S, Landers YM, Jadi-Prat J, Plowin P, Steichen O. Treatment of endocrine diseases: relapse or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis. Eur J Endocrinol. 2016;175(4):R135–45. doi: https://doi.org/10.1530/EJE-16-0189

25. Holscher I, Van Den Berg TJ, Dreijerink KMA, Engelsman AF, Nieveen Van Dijkum EJM. Recurrence Rate of Sporadic Pheochromocytomas after Curative Adrenalectomy: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2021. doi: https://doi.org/10.1210/clinem/dgaa794

26. Plouin PF, Fitzgerald P, Rich T, Ayala-Ramirez M, Perrier ND, Baudin E, et al. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm Metab Res. 2012;44(5):390–399. doi: https://doi.org/10.1055/s-0031–1299707

27. Jiang LL, Wu HH, Bu N, et al. Analysis of clinical features of 42 cases of paraganglioma. Chinese Medical Journal. 2018;(4):280-3

28. Stenman A, Zedenius J, Juhlin CC. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up. Surgery. 2019.

29. Cho YY, Kwak MK, Lee SE, Kim JH, Lee SH. Reply to letter to editor regarding: “a clinical prediction model to estimate the metastatic potential of Pheochromocytoma/paraganglioma: ASES score”. Surgery. 2019;165:853–858. doi: https://doi.org/10.1016/j.surg.2018.11.016

30. Cho YY, Kwak MK, Lee SE, Ahn SH, Kim H, Suh S, et al. A clinical prediction model to estimate the metastatic potential of pheochromocytoma/paraganglioma: ASES score. Surgery. 2018;164:511–517. doi: https://doi.org/10.1016/j.surg.2018.05.001

31. Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016;174(G1-G10) doi: https://doi.org/10.1530/EJE-16-0033

32. Martínez-Morillo E, Valdés Gallego N, Eguia Ángeles E, Fernández Fernández JC, Prieto García B, Álvarez FV. Performance of plasma free metanephrines in diagnosis of pheochromocytomas and paragangliomasin the population of Asturias. Endocrinol Diabetes Nutr. 2019;66(5):312-9. Available from: http://dx.doi.org/10.1016/j.endinu.2018.08.009

33. Samsudin I, Page MM, Hoad K, Chubb P, Gillett M, Glendenning P, et al. Thechallenge of improving the diagnosticyield from metanephrin etesting in suspected phaeochromocytoma and paraganglioma. Ann Clin Biochem. 2018;55(6):679-84. Available from: http://dx.doi.org/10.1177/0004563218774590

34. Konosu-Fukaya S, Omata K, Tezuka Y, Ono Y, Aoyama Y, Satoh F, et al. Catecholamine-synthesizin genzymes in pheochromocytoma and extraadrenal paraganglioma. Endocr Pathol. 2018;29(4):302-9. Available from: http://dx.doi.org/10.1007/s12022-018-9544-5

35. Unger N, Deutschbein T, Walz MK, Mann K, Petersenn S. The value of immunoassays for metanephrines in the biochemical diagnosis of pheochromocytomas. Horm Metab Res. 2009;41(9):676-679

36. van Berkel A, Lenders JW, Timmers HJ. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma. Eur J Endocrinol. 2014;170(3):R109-R119

37. Falhammar H, Kjellman M, Calissendorff J. Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center. Endocrine. 2018;62(3):566-575

38. Endokrinologiya: natsional'noe rukovodstvo / pod red. Dedova I.I. Mel'nichenko G.A. M.: GEOTAR-Media. 2013. 1072 s. (in Rus)

39. Algeciras-Schimnich A, Preissner CM, Young WF, Singh RJ, Grebe SKG. Plasma Chromogranin A or Urine Fractionated Metanephrines Follow-Up Testing Improves the Diagnostic Accuracy of Plasma Fractionated Metanephrines for Pheochromocytoma. J Clin Endocrinol Metab. 2008;93(1):91-95. doi: https://doi.org/10.1210/jc.2007-1354

40. Slavnov V.N., Savitsky S.Yu., Stroganova N.P. Renin angiotensin-aldosterone system in patients with hypertension and endocrine hypertension. — Ukrainian cardiol. Journal, 2013, No. 4, pp.111-116 (in Rus)

41. Дедов И.И., Бельцевич Д.Г., Кузнецов Н.С. и др. Феохромоцитома. М.: Практическая медицина. 2005; 216 с.

42. Mirica RM, Ginghina O, Zugravu G, Iosifescu R, Ionescu M, et al. Retroperitoneal Functioning Paraganglioma--A Rare Case of Secondary Diabetes. Chirurgia (Bucur). 2016;111(2):170-4

43. Isles CG, Johnson JK. Phaeochromocytoma and diabetes mellitus: further evi-dence that alpha 2 receptors inhibit insulin release in man. Clin Endocrinol (Oxf). 1983;18(1):37-41. doi: https://doi.org/10.1111/j.1365-2265.1983.tb03184.x

44. Shustov SB. Cardiac and endocrinea specs of pathogenesis of symptomatic arterial hypertensions. PhD Thesis. St Petersburg, 1993. 42 p. (In Russ)